STAGE IIIA BLADDER CANCER AJCC V8
Clinical trials for STAGE IIIA BLADDER CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IIIA BLADDER CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IIIA BLADDER CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo aims to tame Immunotherapy's side effects in advanced cancers
Disease control OngoingThis study tests whether adding tocilizumab to standard immunotherapy (ipilimumab and nivolumab) can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive the combination to see if it is safer and still eff…
Matched conditions: STAGE IIIA BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
Immunotherapy boost may help bladder cancer patients avoid surgery
Disease control OngoingThis study tests whether adding the immunotherapy drug atezolizumab to standard chemoradiation helps people with muscle-invasive bladder cancer live longer without their cancer returning. About 475 adults with localized disease that hasn't spread are taking part. The goal is to s…
Matched conditions: STAGE IIIA BLADDER CANCER AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 26, 2026 19:37 UTC
-
Bladder cancer survivors: how does treatment really change your life?
Knowledge-focused OngoingThis study follows 204 people with bladder cancer to see how their treatment (surgery or radiation) affects their quality of life. Participants fill out surveys about physical function, pain, fatigue, mood, and bladder, bowel, and sexual health. The goal is to understand which tr…
Matched conditions: STAGE IIIA BLADDER CANCER AJCC V8
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated May 26, 2026 08:45 UTC
-
Can your genes tell if immunotherapy will work? new study investigates
Knowledge-focused OngoingThis study looks at whether specific gene mutations (ARID1A and KDM6A) and a protein called CXCL13 can predict how well the immunotherapy drug nivolumab works in people with advanced bladder cancer that has spread. About 6 participants with these gene changes will receive nivolum…
Matched conditions: STAGE IIIA BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated May 26, 2026 08:29 UTC